205 related articles for article (PubMed ID: 31055976)
1. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.
Peral C; Cordido F; Gimeno-Ballester V; Mir N; Sánchez-Cenizo L; Rubio-Rodríguez D; Rubio-Terrés C
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):105-114. PubMed ID: 31055976
[No Abstract] [Full Text] [Related]
2. Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.
Brue T; Chanson P; Rodien P; Delemer B; Drui D; Marié L; Juban L; Salvi L; Henocque R; Raverot G
Front Endocrinol (Lausanne); 2021; 12():745843. PubMed ID: 34690933
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Acromegaly Treatment: Cost-Utility and Value of Information Analysis.
Leonart LP; Riveros BS; Krahn MD; Pontarolo R
Neuroendocrinology; 2021; 111(4):388-402. PubMed ID: 32299084
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of somatostatin analogues in the treatment of acromegaly.
Orlewska E; Stępień R; Orlewska K
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):15-25. PubMed ID: 30122081
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.
Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome.
Margusino-Framiñán L; Pertega-Diaz S; Pena-Bello L; Sangiao-Alvarellos S; Outeiriño-Blanco E; Pita-Gutierrez F; Pita-Fernandez S; Cordido F
Eur J Intern Med; 2015 Nov; 26(9):736-41. PubMed ID: 26300269
[TBL] [Abstract][Full Text] [Related]
7. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
Chiloiro S; Giampietro A; Mirra F; Donfrancesco F; Tartaglione T; Mattogno PP; Angelini F; Liverana L; Gessi M; Carmelo A; Rindi G; Giustina A; Fleseriu M; Pontecorvi A; De Marinis L; Bianchi A
Eur J Endocrinol; 2021 Feb; 184(2):217-229. PubMed ID: 33136550
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
Ciresi A; Radellini S; Guarnotta V; Giordano C
BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
10. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.
Araujo-Castro M; Biagetti B; Menéndez Torre E; Novoa-Testa I; Cordido F; Pascual-Corrales E; Rodríguez Berrocal V; Guerrero-Pérez F; Vicente A; Percovich Hualpa JC; García-Centeno R; González-Fernández L; Ollero García MD; Irigaray Echarri A; Moure Rodríguez MD; Novo-Rodríguez C; Calatayud M; Villar-Taibo R; Bernabéu I; Alvarez-Escola C; Benítez Valderrama P; Tenorio-Jiménez C; Abellán Galiana P; Venegas E; González-Molero I; Iglesias P; Blanco-Carrera C; Vidal-Ostos De Lara F; de Miguel Novoa P; López Mezquita E; Hanzu FA; Aldecoa I; Aznar S; Lamas C; Aulinas A; Asla Q; Gracia Gimeno P; Recio-Córdova JM; Avilés-Pérez MD; Asensio-Wandosell D; Sampedro-Núñez M; Cámara R; Paja Fano M; Ruz-Caracuel I; Fajardo C; Marazuela M; Puig-Domingo M
Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38713182
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
De Marinis L; Bianchi A; Fusco A; Cimino V; Mormando M; Tilaro L; Mazziotti G; Pontecorvi A; Giustina A
Pituitary; 2007; 10(3):227-32. PubMed ID: 17484056
[TBL] [Abstract][Full Text] [Related]
13. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
14. Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain.
Sánchez-Cenizo L; Aller J; Martínez-Sesmero JM; Mir N; Peral C; Rubio-Rodríguez D; Rubio-Terrés C
Clinicoecon Outcomes Res; 2019; 11():465-475. PubMed ID: 31413609
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.
Muhammad A; Coopmans EC; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2018 Oct; 179(5):269-277. PubMed ID: 30076159
[TBL] [Abstract][Full Text] [Related]
16. Pasireotide: potential treatment option for McCune-Albright-associated acromegaly.
Ilie MD; Raverot G; Brac de la Perrière A
Eur J Endocrinol; 2024 Jan; 190(1):K17-K20. PubMed ID: 38128124
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
[TBL] [Abstract][Full Text] [Related]
19. Investigational therapies for acromegaly.
Grasso LF; Pivonello R; Colao A
Expert Opin Investig Drugs; 2013 Aug; 22(8):955-63. PubMed ID: 23731031
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of acromegaly treatments: a systematic review.
Leonart LP; Borba HHL; Ferreira VL; Riveros BS; Pontarolo R
Pituitary; 2018 Dec; 21(6):642-652. PubMed ID: 30159696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
